Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp has demonstrated strong financial performance, with contracted revenue increasing by 30% year-over-year and substantial outperformance in margins and earnings per share (EPS). The company's revenue guidance for 2025 exceeds consensus expectations by 13-17%, indicating a robust growth outlook as it adapts to the shift toward digital interactions in healthcare. Additionally, visibility for 2025 revenue has improved significantly, suggesting over 85% predictability, while the 2025 EBITDA guidance also surpasses consensus, reinforcing a positive financial trajectory.

Bears say

The financial performance of OptimizeRx Corp shows several concerning trends, including a decline in revenue growth rates and increasing operational expenses, which have negatively impacted profitability margins. Additionally, the company faces significant competition in the digital healthcare messaging space and may struggle to maintain its market share and client relationships amidst rising operational costs. Furthermore, inefficient capital allocation and increased cash burn rates raise questions about the company's long-term sustainability and ability to invest in growth initiatives effectively.

OptimizeRx Corp (OPRX) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 4 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.